CMS Introduces Initiative to Enhance GLP-1 Availability in Medicaid and Medicare Part D

Program Overview

The Trump administration unveiled an innovative demonstration initiative designed to simplify access to GLP-1 receptor agonists for participants in Medicare Part D and Medicaid programs, although specialists express doubts about its potential popularity and success.

Dubbed Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE), the initiative focuses on expanding availability of GLP-1 medications for "weight management and metabolic health enhancement" among Medicare Part D and Medicaid beneficiaries. BALANCE "expands on our groundbreaking Most Favored Nations drug pricing agreements' aim of making weight-loss treatments available to those who have been excluded," stated Mehmet Oz, MD, MBA, CMS administrator, in a press statement. "Through the BALANCE Model, we combine cutting-edge science with wholesome habits to reduce expenses and enable Americans to manage their well-being."

Negotiations and Features

CMS intends to engage with pharmaceutical companies, who will join voluntarily, to decrease prices for these medications. Key negotiation points encompass:

• Fixed net pricing and possible limits on out-of-pocket costs for recipients
• Uniform eligibility standards
• Science-backed lifestyle assistance programs (such as guidance on sustaining weight reduction and adopting healthier choices)

Further details on state and Part D plan involvement will emerge in early 2026, according to CMS, with the model slated to begin in Medicaid no later than May 2026 and in Medicare Part D by January 2027.

For Medicare Part D participants, "CMS intends to roll out a fresh GLP-1 payment demonstration starting July 2026, acting as a temporary link to the BALANCE Model launching in 2027," the agency noted on its website. "Individuals covered under Medicare Part D meeting the agreed-upon criteria will gain entry to these medications. Qualified Medicare recipients will incur a $50 monthly fee for GLP-1 treatments."

Expert Insights on Cost Reduction

Will this initiative genuinely cut GLP-1 expenses for users? The outcome hinges on multiple elements, per Stacey Lee, a law and ethics professor at Johns Hopkins University Bloomberg School of Public Health in Baltimore. "Regarding availability, the model might offer marginal improvements, but it's improbable to bring about extensive, consistent growth independently," Lee commented in an email. "Obstacles to GLP-1 availability extend beyond medical factors. They include economic and bureaucratic hurdles. Without substantially altering pricing structures or usage restrictions, numerous Medicare and Medicaid recipients will continue encountering coverage restrictions."

Yet Theodora "Teddy" McCormick from the Baker Donelson law firm in Princeton, New Jersey, showed greater enthusiasm. "What's intriguing is that CMS will negotiate straight with manufacturers, creating a genuine opportunity to broaden availability," she remarked, observing that alternative CMS price talks, like those under the Inflation Reduction Act, rely on pharmacy benefit managers as intermediaries. Additionally, "Medicare currently permits GLP-1 use only for heart-related conditions and diabetes," but these drugs lack approval for Medicare reimbursement purely for weight loss, making this trial program an extension of applications.

Marsha Simon, PhD, an adjunct health policy professor at George Washington University in Washington, expressed interest in the broader reimbursement scope for GLP-1s. From a macro viewpoint, "it would prove highly beneficial if the administration tackled the Part D legal ban on weight-loss medications," she wrote via email. However, "I recognize the hesitation to proceed without resolving the Medicare reimbursement foundation, which, following a judicial ruling, bars CMS from factoring in the expense of a service or drug."

"Consequently, Congress must revisit the issue of whether expenses should influence Medicare reimbursement," she added.

Nonetheless, Simon cautioned, "I wouldn't anticipate rapid action, given Congress's struggles with even simpler matters, such as prolonging or reforming [Affordable Care Act] subsidy extensions and cost-sharing aids."

Simon also doubted the administration's capacity to markedly reduce GLP-1 prices. "Despite competition between Lilly and Novo Nordisk in this sector, I'm uncertain the administration can secure better rates than Part D providers—particularly since they are also bargaining lower prices for their Trump Rx direct-to-consumer sales platform, priced at $350 monthly without insurance," she explained. "Presently, Lilly provides [tirzepatide (Zepbound)] directly to customers at roughly $250 per month, appearing to be the most favorable deal manufacturers wish to extend."

State Medicaid Participation Uncertainty

Participation by state Medicaid programs remains another unresolved issue. Though Medicaid programs already benefit from "best price" safeguards via the Medicaid Drug Rebate Program, "the best price doesn't guarantee optimal access," stated Lee from Johns Hopkins. "Elevated list prices still result in limited drug lists, pre-approval needs, and exclusionary policies. A trial model will assist only if it significantly overcomes these secondary challenges, beyond just the primary discount."

Regarding state Medicaid interest, "I foresee inconsistent adoption," she predicted. "Regions with prevalent metabolic disorders and robust managed care systems might opt for prompt involvement. Conversely, others may exercise caution due to prolonged fiscal risks from ongoing high-cost medication use. I expect a select few pioneers rather than widespread, instant engagement."

McCormick noted that while obesity rates differ across states, "most insurers and [state] authorities are beginning to acknowledge obesity's substantial long-term financial implications, and to the degree we can assist those affected, it will yield positive results... States will evaluate this through a financial and formulary lens, yet significant advantages exist."

Ultimately, Lee concluded, "The central issue isn't whether GLP-1s are effective. We know they are. It's about whether this framework genuinely reallocates bargaining influence to ensure lasting availability for Medicare and Medicaid patients."